PP2A inhibition with LB100 enhances cisplatin cytotoxicity and overcomes cisplatin resistance in medulloblastoma cells

Oncotarget - Tập 7 Số 11 - Trang 12447-12463 - 2016
Winson S. Ho1, Michael J. Feldman1, Dragan Maric2, Lauren Amable3, Matthew D. Hall4, Gerald M. Feldman5, Abhik Ray‐Chaudhury1, Martin J. Lizak6, Juan C. Vera7, Aaron Robison8, Zhengping Zhuang1, John D. Heiss1
1Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892.
2NINDS Flow Cytometry Core Facility, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892
3National Institute on Minority Health and Health Disparities, National Institutes of Health, Bethesda, MD 20892
4National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA
5Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993
6In Vivo NMR Center, National Institute of Neurological Disorder and Stroke, National Institutes of Health, Bethesda, MD 20892
7School of Medicine, Tulane University, New Orleans, LA 70112
8Division of Neurosurgery, Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA 90027

Tóm tắt

Từ khóa


Tài liệu tham khảo

Kruchko, 2012, CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009, Neuro Oncol, 14, v1, 10.1093/neuonc/nos218

Gajjar, 2013, Survival, secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961, Neuro-oncology, 15, 97, 10.1093/neuonc/nos267

Cole, 2014, Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group, Acta Neuropathol, 127, 189, 10.1007/s00401-013-1213-7

Orecchia, 2009, Pediatric medulloblastoma: toxicity of current treatment and potential role of protontherapy, Cancer Treat Rev, 35, 79, 10.1016/j.ctrv.2008.09.002

Doz, 2009, From childhood to adulthood: long-term outcome of medulloblastoma patients. The Institut Curie experience (1980-2000), J Neurooncol, 95, 271, 10.1007/s11060-009-9927-z

Finlay, 2010, High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma, Neuro Oncol, 12, 297, 10.1093/neuonc/nop031

von Bueren, 2012, Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas, Acta Neuropathol, 123, 473, 10.1007/s00401-012-0958-8

Packer, 2015, Medulloblastoma: toward biologically based management, Semin Pediatr Neurol, 22, 6, 10.1016/j.spen.2014.12.010

Zhuang, 2015, LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential, Cancer Biol Ther, 16, 821, 10.1080/15384047.2015.1040961

Neviani, 2013, Protein phosphatase 2A: a target for anticancer therapy, Lancet Oncol, 14, e229, 10.1016/S1470-2045(12)70558-2

Mumby, 2007, PP2A: unveiling a reluctant tumor suppressor, Cell, 130, 21, 10.1016/j.cell.2007.06.034

Zhuang, 2009, Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms, Proc Natl Acad Sci U S A, 106, 11697, 10.1073/pnas.0905930106

Vincent Chung, Fadi, Carlos, Donald. 2015. Phase I Study of LB-100 With Docetaxel in Solid Tumors.

Gottesman, 2015, The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity, Mol Cancer Ther, 14, 90, 10.1158/1535-7163.MCT-14-0496

Zhou, 2015, Inhibition of protein phosphatase 2A with the small molecule LB100 overcomes cell cycle arrest in osteosarcoma after cisplatin treatment, Cell Cycle, 14, 2100, 10.1080/15384101.2015.1041693

Liang, 2014, Inhibition of protein phosphatase 2A enhances cytotoxicity and accessibility of chemotherapeutic drugs to hepatocellular carcinomas, Mol Cancer Ther, 13, 2062, 10.1158/1535-7163.MCT-13-0800

Chen, 2015, Protein Phosphatase 2A Inhibition with LB100 Enhances Radiation-Induced Mitotic Catastrophe and Tumor Growth Delay in Glioblastoma, Mol Cancer Ther, 14, 1540, 10.1158/1535-7163.MCT-14-0614

Zeng, 2014, Inhibition of protein phosphatase 2A with a small molecule LB100 radiosensitizes nasopharyngeal carcinoma xenografts by inducing mitotic catastrophe and blocking DNA damage repair, Oncotarget, 5, 7512, 10.18632/oncotarget.2258

Morgan, 2013, Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancers by modulating CDC25C/CDK1 and homologous recombination repair, Clin Cancer Res, 19, 4422, 10.1158/1078-0432.CCR-13-0788

Jove, 2014, Revisiting STAT3 signalling in cancer: new and unexpected biological functions, Nat Rev Cancer, 14, 736, 10.1038/nrc3818

Govoni, 1998, Variations in the levels of the JAK/STAT and ShcA proteins in human brain tumors, Anticancer Res, 18, 2381

Schaefer, 2002, Constitutive activation of Stat3alpha in brain tumors: localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor (VEGFR-2), Oncogene, 21, 2058, 10.1038/sj.onc.1205263

Jove, 2008, Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas, Mol Cancer Ther, 7, 3519, 10.1158/1535-7163.MCT-08-0138

Dilloo, 2014, In comparative analysis of multi-kinase inhibitors for targeted medulloblastoma therapy pazopanib exhibits promisingandefficacy, Oncotarget, 5, 7149, 10.18632/oncotarget.2240

Lin, 2015, A novel small molecular STAT3 inhibitor, LY5, inhibits cell viability, cell migration, and angiogenesis in medulloblastoma cells, J Biol Chem, 290, 3418, 10.1074/jbc.M114.616748

Yu, 2010, Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways, Mol Cancer Res, 8, 35, 10.1158/1541-7786.MCR-09-0220

Liu, 2012, Inhibition of phosphorylated STAT3 by cucurbitacin I enhances chemoradiosensitivity in medulloblastoma-derived cancer stem cells, Childs Nerv Syst, 28, 363, 10.1007/s00381-011-1672-x

Ma, 2014, Celecoxib suppresses the phosphorylation of STAT3 protein and can enhance the radiosensitivity of medulloblastoma-derived cancer stem-like cells, Int J Mol Sci, 15, 11013, 10.3390/ijms150611013

Odum, 1999, Inhibition of protein phosphatase 2A induces serine/threonine phosphorylation, subcellular redistribution, and functional inhibition of STAT3, Proc Natl Acad Sci U S A, 96, 10620, 10.1073/pnas.96.19.10620

Kikuchi, 2005, Protein phosphatase type 2A, PP2A, is involved in degradation of gp130, Mol Cell Biochem, 269, 183, 10.1007/s11010-005-3089-x

Ghosh, 2014, Reduced phosphorylation of Stat3 at Ser-727 mediated by casein kinase 2 - protein phosphatase 2A enhances Stat3 Tyr-705 induced tumorigenic potential of glioma cells, Cell Signal, 26, 1725, 10.1016/j.cellsig.2014.04.003

Schmidt, 2013, Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma, Cell, 152, 1065, 10.1016/j.cell.2013.01.036

Bouffet, 2013, Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children, Cancer Res, 73, 6734, 10.1158/0008-5472.CAN-12-4331

Ma, 2015, Cisplatin-selected resistance is associated with increased motility and stem-like properties via activation of STAT3/Snail axis in atypical teratoid/rhabdoid tumor cells, Oncotarget, 6, 1750, 10.18632/oncotarget.2737

Cole, 2014, Multidrug resistance protein 1 (MRP1, ABCC1), a "multitasking" ATP-binding cassette (ABC) transporter, J Biol Chem, 289, 30880, 10.1074/jbc.R114.609248

Popovic, 2005, Survivin is a negative prognostic marker in medulloblastoma, Neuropathol Appl Neurobiol, 31, 422, 10.1111/j.1365-2990.2005.00664.x

Marshall, 2012, Subgroup-specific structural variation across 1,000 medulloblastoma genomes, Nature, 488, 49, 10.1038/nature11327

Bonavida, 2014, Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention, J Exp Clin Cancer Res, 33, 62, 10.1186/s13046-014-0062-0

De Braganca, 2015, Medulloblastoma, J Child Neurol

Gottesman, 2012, Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes, Pharmacol Rev, 64, 706, 10.1124/pr.111.005637

Gottesman, 2014, Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes, Cancer Res, 74, 3913, 10.1158/0008-5472.CAN-14-0247